Diamedica therapeutics inc. (DMAC)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-9,822

-10,649

-10,131

-9,070

-8,336

-5,734

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation

1,427

1,164

828

487

597

620

0

0

0

Amortization of discount on marketable securities

62

74

0

0

0

-

-

-

-

Non-cash lease expense

50

49

0

0

0

-

-

-

-

Depreciation

21

21

21

20

17

15

0

0

0

Change in fair value of warrant liability

-

-

-

-

-

39

0

0

0

Changes in operating assets and liabilities:
Amounts receivable

55

43

-379

790

141

700

0

0

0

Prepaid expenses

40

-322

-71

88

249

308

0

0

0

Deposits

0

-

-

-

-

-

-

-

-

Accounts payable

-240

-301

63

-190

201

-30

0

0

0

Accrued liabilities

-301

226

-297

-83

30

402

0

0

0

Net cash used in operating activities

-8,946

-9,102

-9,137

-9,743

-7,895

-5,696

0

0

0

Cash flows from investing activities:
Purchase of marketable securities

10,790

12,919

0

0

0

-

-

-

-

Maturities of marketable securities

0

-

-

-

-

-

-

-

-

Purchase of property and equipment

0

-

-

-

-

50

0

0

0

Net cash used in investing activities

1,719

-3,908

-4,903

-7,924

-10,946

-50

0

0

0

Cash flows from financing activities:
Proceeds from issuance of common shares, net of offering costs

0

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options

0

-

-

-

-

-

-

-

-

Principal payments on finance lease obligations

5

5

0

0

0

-

-

-

-

Proceeds from issuance of common shares and warrants, net offering costs

-

-

-

-

-

5,840

0

0

0

Proceeds from the exercise of common share purchase warrants

-

-

-

-

-

607

0

0

0

Net cash provided by financing activities

7,768

70

14,883

14,915

14,890

21,216

0

0

0

Net decrease in cash and cash equivalents

541

-12,940

843

-2,752

-3,951

15,470

0

0

0